JNJ vs PFE: Dividend Comparison
Dividend data as of
Johnson & Johnson (JNJ) and Pfizer Inc (PFE) are both in the Health Care sector, making them natural rivals for dividend investors. PFE offers a significantly higher 6.23% yield compared to JNJ's 2.16%, a gap of 4.07%. For dividend growth, PFE leads with a 5-year CAGR of 10.1% versus JNJ's 5.2%. Both stocks carry a "Safe" dividend safety rating. JNJ is a Dividend King with 63 years of consecutive increases.
Verdict
Yield Analysis
PFE yields 4.07% more than JNJ. In dollar terms, JNJ pays $5.14/share vs PFE's $1.72/share annually.
Dividend Growth
JNJ: Dividend growth is slowing — the 3-year CAGR of 4.6% trails the 5-year rate of 5.2% and the 10-year rate of 5.6%.
PFE: Dividend growth is accelerating — the 3-year CAGR of 18.3% exceeds the 5-year rate of 10.1% and the 10-year rate of 8.1%.
Dividend Safety
JNJ: The payout ratio of 47% is well within sustainable levels, leaving room for future increases. Earnings cover the dividend 2.1x.
PFE: The payout ratio of 1% is well within sustainable levels, leaving room for future increases. Earnings cover the dividend 0.8x.
Estimated Annual Dividend Income
Based on current dividend yields. Actual income may vary.
What does $10,000 buy in JNJ vs PFE today?
At $243.53 per share, $10,000 buys about 41.1 shares of Johnson & Johnson (JNJ). Each share pays $5.14 per year in dividends, so the position starts out generating roughly $211 per year — about $18 a month.
At $27.80 per share, $10,000 buys about 359.8 shares of Pfizer Inc (PFE). Each share pays $1.72 per year in dividends, so the position starts out generating roughly $619 per year — about $52 a month.
PFE is the larger income stream from day one: $408 per year more on the same $10,000 invested.
What could $10,000 of JNJ or PFE income look like in 10 years?
Johnson & Johnson (JNJ) has raised its dividend about 5.2% a year over the past five years. If that pace held, the $216 per year that $10,000 generates today at the current 2.16% yield would reach $359 per year by 2036 — a 3.6% yield on the original cost.
Pfizer Inc (PFE) has raised its dividend about 10.1% a year over the past five years. If that pace held, the $623 per year that $10,000 generates today at the current 6.23% yield would reach $1,632 per year by 2036 — a 16.3% yield on the original cost.
On those trailing rates, PFE pays more in 2036: $1,632 versus $359 per year. The projection assumes each five-year growth rate persists and no dividends are reinvested — real payouts will differ.
When would JNJ's dividend growth overtake PFE's higher yield?
It doesn't, on the trailing numbers. Pfizer Inc (PFE) yields more today (6.23% vs 2.16%) and has also grown its dividend at least as fast (10.1% vs 5.2% a year over five years). Unless JNJ accelerates its raises or PFE stumbles, JNJ never closes the income gap — PFE wins on both current income and growth.
Can JNJ and PFE afford their dividends?
Johnson & Johnson (JNJ) earns $11.03 per share against $5.14 paid out in dividends — 2.1x coverage (a 47% payout ratio).
Pfizer Inc (PFE) earns $1.36 per share against $1.72 paid out in dividends — 0.8x coverage (a 1% payout ratio).
JNJ's wider coverage leaves more cushion if earnings dip. As a rule of thumb, coverage below about 1.5x (a payout ratio above ~65%) is where a dividend starts to look stretched — worth watching for PFE if earnings weaken.
Which fits an early-retirement income portfolio better, JNJ or PFE?
For income you need right now, Pfizer Inc (PFE) leads: $100,000 invested today pays about $519 a month at the current 6.23% yield, versus $180 a month from Johnson & Johnson (JNJ) at 2.16%.
PFE also leads on dividend growth (10.1% vs 5.2% a year over five years), so the trailing numbers favor it on both fronts.
On consistency: JNJ has raised its dividend 63 consecutive years.
Many income investors simply hold both — the mix pairs current yield with growth and spreads single-name risk. Whichever way you lean, dividends are never guaranteed; recheck the payout each quarter rather than setting and forgetting.
$10,000 with DRIP: projected annual income
If each holding keeps raising its dividend at its real 5-year rate and every payment is reinvested, a $10,000 position pays $445/yr in JNJ vs $2,987/yr in PFE by year 10.
Assumes dividends are reinvested at the current yield and grow at each holding's trailing 5-year dividend CAGR. A projection, not a prediction — no price appreciation modeled.
Track JNJ and PFE in your portfolio
See your real income from both — forward projections, yield on cost, and dividend safety signals. Sync your brokerage free for 30 days, or track holdings manually on the free plan.
Frequently Asked Questions
Related Resources
Individual Stock Analysis
Dividend Tools
Track Your Dividends
More Comparisons
This tool is for educational and informational purposes only and does not constitute investment, financial, tax, or legal advice. Consult a licensed professional before making investment decisions.
Past performance does not guarantee future results. All projections are hypothetical estimates based on user-provided inputs and may differ materially from actual outcomes.
By using this tool you agree to our Terms of Service and Privacy Policy.